October 2025 in “Journal of Clinical Medicine” This study investigated predictors of early response to baricitinib in 44 patients with severe alopecia areata. It found that early responders, who made up 34.1% of the cohort, were more likely to have a lower baseline Severity of Alopecia Tool (SALT) score, shorter disease duration, and elevated erythrocyte sedimentation rate (ESR) at baseline. The study suggests that these clinical and laboratory parameters can help identify patients who are most likely to benefit from baricitinib treatment, highlighting a therapeutic window of opportunity for those with lower disease burden and shorter disease duration.
51 citations
,
April 1999 in “The Journal of Steroid Biochemistry and Molecular Biology” Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.
January 2010 in “HAL (Le Centre pour la Communication Scientifique Directe)” Magnesium and caspase inhibitors help protect hearing after gunshot noise.
26 citations
,
December 2016 in “Pharmacology & Therapeutics” New drugs for heart disease may be developed from molecules secreted by stem cells.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.